VEGF-A₁₂₁assay

摘要

The invention provides a method for enriching the level of VEGF-A121 isoform in a sample by selectively removing the VEGF-A165 isoform from the sample using a neuropilin-1 pull-down procedure, then determining the total amount of VEGF-A remaining afterward. The invention provides methods of treating a patient suffering from a disease which may benefit from the administration of a VEGF antagonist by determining the level or ratio of VEGF-A121 in the patient's circulation. Methods of diagnosis, prognosis, monitoring, and patient stratification are also provided.

主权项

1. A method of treating cancer, comprising, (a) obtaining a blood sample from a patient who suffers from cancer; (b) enriching the amount of VEGF-A121 in the sample by the steps of:
contacting the sample comprising VEGF-A165 and VEGF-A121 with (1) a neuropilin 1 (“NRP1”) protein, or (2) a fraction of the NRP1 protein comprising the B1B2 domain, wherein the VEGF-A165 binds to the NRP1 protein or fraction thereof to form a NRP1-VEGF-A165 complex; and separating the sample from the NRP1-VEGF-A165 complex to form a VEGF-A165-depleted sample; (c) quantifying the total remaining VEGF-A in the VEGF-A165-depleted sample; wherein the total remaining VEGF-A is enriched for VEGF-A121; and (d) administering a VEGF antagonist, if the total remaining VEGF-A is above a threshold amount.